NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has rescheduled its second quarter 2025 financial results release to August 19, 2025 after market close. The company will host a conference call the following morning on August 20, 2025, at 8:00 AM ET.
The delay is due to the company requiring additional time to compile certain information and recent developments into their Form 10-Q filing. Investors can access the results via press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).
NRx Pharmaceuticals (NASDAQ:NRXP), una società biofarmaceutica in fase clinica, ha riprogrammato la pubblicazione dei risultati finanziari del secondo trimestre 2025 al 19 agosto 2025 dopo la chiusura del mercato. La società terrà una conference call la mattina successiva, 20 agosto 2025 alle 8:00 ET.
Il rinvio è dovuto alla necessità di disporre di più tempo per compilare alcune informazioni e gli sviluppi recenti nel loro Form 10-Q. Gli investitori potranno consultare i risultati tramite comunicato stampa sul sito della società e partecipare alla conference call via webcast o chiamando il +1-800-717-1738 (nazionale) o il +1-646-307-1865 (internazionale).
NRx Pharmaceuticals (NASDAQ:NRXP), una compañía biofarmacéutica en fase clínica, ha reprogramado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 19 de agosto de 2025 tras el cierre del mercado. La empresa celebrará una conferencia telefónica a la mañana siguiente, 20 de agosto de 2025 a las 8:00 ET.
El retraso se debe a que la compañía necesita más tiempo para compilar cierta información y desarrollos recientes en su Form 10-Q. Los inversores podrán consultar los resultados mediante un comunicado de prensa en la web de la compañía y unirse a la conferencia por webcast o llamando al +1-800-717-1738 (nacional) o al +1-646-307-1865 (internacional).
NRx Pharmaceuticals (NASDAQ:NRXP)는 임상 단계의 바이오제약사로서 2025년 2분기 재무실적 발표를 2025년 8월 19일 장 마감 후로 다시 일정 조정했습니다. 회사는 다음 날인 2025년 8월 20일 오전 8:00 ET에 컨퍼런스 콜을 진행할 예정입니다.
이번 연기는 일부 정보와 최근 진행 상황을 Form 10-Q에 반영하기 위해 추가 시간이 필요했기 때문입니다. 투자자들은 회사 웹사이트의 보도자료를 통해 실적을 확인할 수 있으며, 웹캐스트로 참여하거나 +1-800-717-1738 (국내) 또는 +1-646-307-1865 (국제)로 전화해 컨퍼런스 콜에 참석할 수 있습니다.
NRx Pharmaceuticals (NASDAQ:NRXP), une société biopharmaceutique en phase clinique, a reprogrammé la publication de ses résultats financiers du deuxième trimestre 2025 au 19 août 2025 après la clôture du marché. La société tiendra une conférence téléphonique le lendemain matin, le 20 août 2025 à 8h00 ET.
Ce report s'explique par le besoin de temps supplémentaire pour intégrer certaines informations et les développements récents dans son Form 10-Q. Les investisseurs pourront consulter les résultats via un communiqué de presse sur le site de la société et participer à la conférence par webcast ou en appelant le +1-800-717-1738 (national) ou le +1-646-307-1865 (international).
NRx Pharmaceuticals (NASDAQ:NRXP), ein biopharmazeutisches Unternehmen in klinischer Phase, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 auf den 19. August 2025 nach Börsenschluss verschoben. Das Unternehmen wird am folgenden Morgen eine Telefonkonferenz abhalten, 20. August 2025 um 8:00 Uhr ET.
Die Verzögerung ist darauf zurückzuführen, dass das Unternehmen mehr Zeit benötigt, um bestimmte Informationen und aktuelle Entwicklungen in seine Form 10-Q aufzunehmen. Anleger können die Ergebnisse über eine Pressemitteilung auf der Unternehmenswebsite abrufen und der Telefonkonferenz per Webcast oder per Anruf unter +1-800-717-1738 (national) bzw. +1-646-307-1865 (international) beitreten.
- None.
- None.
Conference Call 8:00am ET, Wednesday August 20, 2025
The Company requires additional time to compile certain information, including recent developments, into the Form 10-Q necessary for a complete presentation, which it is unable to complete without unreasonable effort.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: | |
Matthew Duffy | Brian Korb |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, astr Partners |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-reschedules-second-quarter-2025-financial-results-release-to-august-19-2025-302529491.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRx Pharmaceuticals (NRXP) release Q2 2025 earnings?
How can investors access NRXP's Q2 2025 earnings call?
What time is NRx Pharmaceuticals' Q2 2025 earnings call?
Why did NRXP reschedule their Q2 2025 earnings release?
